Markets:

Overview

News

Currencies

International

Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

9.930 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines ↗

February 11, 2025

The company could soon add a new, high-value treatment to its portfolio.

Via Investor's Business Daily

Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force ↗

January 26, 2025

The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force dedicated to the development of a clear and comprehensive regulatory...

Via Benzinga

Topics Regulatory Compliance

What's Going On With Merus Stock Monday? ↗

January 13, 2025

Merus announced a research collaboration and license agreement with Biohaven.

Via Benzinga

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

January 12, 2025

From Merus N.V.

Via GlobeNewswire

BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024 ↗

August 09, 2024

BHVN stock results show that Biohaven missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval ↗

December 17, 2024

Biohaven's BHV-1300 shows >60% IgG reduction in early trials with promising safety data, advancing its MoDE platform and regulatory milestones.

Via Benzinga

Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio? ↗

December 01, 2024

8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.

Via Benzinga

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study ↗

November 25, 2024

Biohaven reported taldefgrobep data showing motor function gains in SMA and plans to advance obesity studies with an autoinjector in 4Q24.

Via Benzinga

Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 25, 2024

Via Benzinga

Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy ↗

October 07, 2024

The company is hoping to treat patients with spinal muscular atrophy, a muscle-wasting disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 07, 2024

Via Benzinga

Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday ↗

October 01, 2024

Via Benzinga

Hewlett Packard Enterprise, Nvidia, Progress Software And Other Big Stocks Moving Higher On Wednesday ↗

September 25, 2024

Via Benzinga

Biohaven Stock Soars on Drug Trial Results: Time to Jump In?

September 24, 2024

Biohaven, a clinical-stage biopharmaceutical company, is attracting investors with promising results for its experimental drug.

Via MarketBeat

Dow Gains Over 50 Points; Elevai Labs Shares Plummet ↗

September 23, 2024

Via Benzinga

Topics Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 23, 2024

Via Benzinga

Crude Oil Down Over 1%; US Manufacturing PMI Falls In September ↗

September 23, 2024

Via Benzinga

Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise ↗

September 23, 2024

Biohaven announced topline results from its pivotal Study BHV4157-206-RWE, showing that troriluzole significantly slowed disease progression in spinocerebellar ataxia patients over three years. The...

Via Benzinga

Biohaven, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 23, 2024

Via Benzinga

Biohaven Surges After Delaying Progression By Up To 70% In A Rare Disease ↗

September 23, 2024

The company is hoping to soon file for approval of what could be the first SCA treatment.

Via Investor's Business Daily

This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗

September 16, 2024

Via Benzinga

Biohaven Stock Earns Relative Strength Rating Upgrade ↗

August 21, 2024

Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.

Via Investor's Business Daily

$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying ↗

July 22, 2024

Via Benzinga

The 3 Smartest Healthcare Stocks to Buy With $1K Right Now ↗

June 28, 2024

The healthcare stocks to buy deserve more respect from investors who seek top-level growth outside of the tech sector.

Via InvestorPlace

HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday ↗

May 30, 2024

Via Benzinga

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗

May 30, 2024

Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.

Via Investor's Business Daily

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗

May 29, 2024

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 29, 2024

Via Benzinga

What's Going On With Biohaven Stock Wednesday? ↗

May 29, 2024

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.